이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

표피 성장 인자 수용체(EGRF) 변이 비소세포폐암(NSCLC)에서 아미반타맙+레이저티닙으로 1차 치료를 받은 경우 발진과 조갑주위염을 줄이기 위한 강화된 피부과 치료 (COCOON)

2026년 11월 2일 업데이트: Janssen Research & Development, LLC

아미반타맙 + 레이저티닙으로 1차 치료를 받은 국소 진행성 또는 전이성 EGFR 변이 비소세포폐암 환자를 대상으로 특정 피부 이상반응에 대한 강화된 피부과적 관리와 표준 피부과적 관리의 영향을 평가하는 2상 공개 무작위 임상시험

The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management and with modified enhanced dermatologic management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib. The study also includes Expansion cohorts (in 2 different schedules) to evaluate enhanced dermatologic management and early intervention for DAEIs or paronychia, in participants receiving subcutaneous amivantamab and lazertinib. A substudy will enroll participants from Arms A and B who experience specific new-onset or persistent DAEIs (Grade >=2) during treatment with intravenous (IV) amivantamab and lazertinib. This substudy aims to assess the reactive use of dermatologic treatment strategies in these participants.

연구 개요

연구 유형

중재적

등록 (실제)

305

단계

  • 2 단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Hsinchu, 대만, 30059
        • National Taiwan University Hospital Hsin Chu Branch
      • Kaohsiung City, 대만, 833
        • Chang Gung Memorial Hospital
      • Taichung, 대만, 40705
        • Taichung Veterans General Hospital
      • Taipei, 대만, 100
        • National Taiwan University Hospital
      • Taoyuan City, 대만, 333
        • Linkou Chang Gung Memorial Hospital
      • Cheongju-si, 대한민국, 28644
        • Chungbuk National University Hospital
      • Incheon, 대한민국, 21565
        • Gachon University Gil Medical Center
      • Seoul, 대한민국, 03722
        • Severance Hospital Yonsei University Health System
      • Aachen, 독일, 52074
        • Universitaetsklinikum der RWTH Aachen
      • Essen, 독일, 45136
        • Kliniken Essen-Mitte
      • Giessen, 독일, 35392
        • Universitaetsklinikum Giessen und Marburg GmbH
      • Heidelberg, 독일, 69126
        • Thoraxklinik am Universitatsklinikum Heidelberg
      • Kassel, 독일, 34125
        • Klinikum Kassel GmbH
      • Kiel, 독일, 24105
        • Universitaetsklinikum Schleswig Holstein Campus Kiel
      • George Town, 말레이시아, 10450
        • Hospital Pulau Pinang
      • Kuala Lumpur, 말레이시아, 59100
        • University Malaya Medical Centre
      • Kuantan, 말레이시아, 25100
        • Hospital Tengku Ampuan Afzan
      • Kuching, 말레이시아, 93586
        • Hospital Umum Sarawak
    • Arizona
      • Chandler, Arizona, 미국, 85224
        • Ironwood Cancer and Research Center
    • California
      • Duarte, California, 미국, 91010
        • City of Hope
      • Fullerton, California, 미국, 92835
        • Providence Fullerton
      • Glendale, California, 미국, 91204
        • Los Angeles Cancer Network
      • Huntington Beach, California, 미국, 92648
        • City of Hope Seacliff
      • Irvine, California, 미국, 92618
        • City of Hope Orange County Lennar Foundation Cancer Center
      • Long Beach, California, 미국, 90813
        • City of Hope Long Beach Elm
      • Los Alamitos, California, 미국, 90720
        • Cancer and Blood Specialty Clinic
      • Los Angeles, California, 미국, 90033
        • Keck Hospital of USC
      • Newport Beach, California, 미국, 92663
        • USC Norris Oncology Hematology Newport Beach
      • Oakland, California, 미국, 94611
        • Kaiser Permanente Oakland Medical Center
      • Roseville, California, 미국, 95661
        • Kaiser Permanente Roseville Medical Center
      • San Francisco, California, 미국, 94115
        • Kaiser Permanente San Francisco Medical Center
      • Santa Clara, California, 미국, 95051
        • Kaiser Permanente Santa Clara Medical Center
      • South Pasadena, California, 미국, 91030
        • City of Hope South Pasadena
      • Vallejo, California, 미국, 94589
        • Kaiser Permanente Northern California
      • Walnut Creek, California, 미국, 94596
        • Kaiser Permanente Walnut Creek Medical Center
    • Georgia
      • Athens, Georgia, 미국, 30607
        • University Cancer & Blood Center
    • Illinois
      • Hinsdale, Illinois, 미국, 60521
        • Hope and Healing Care
    • Missouri
      • Springfield, Missouri, 미국, 65807
        • Oncology Hematology Associates
    • Nevada
      • Reno, Nevada, 미국, 89502
        • Renown Health Medical Oncology
    • New Jersey
      • Flemington, New Jersey, 미국, 08822
        • Hunterdon Hematology Oncology
    • New York
      • Westbury, New York, 미국, 11590
        • Clinical Research Alliance Inc
    • North Carolina
      • Wilson, North Carolina, 미국, 27893
        • Regional Medical Oncology Center
    • Ohio
      • Cleveland, Ohio, 미국, 44106
        • University Hospitals Cleveland Medical Center
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Virginia Cancer Specialists
    • Washington
      • Renton, Washington, 미국, 98055
        • Valley Medical Center
    • Wisconsin
      • West Salem, Wisconsin, 미국, 54669
        • Gundersen Health System
      • Belo Horizonte, 브라질, 30150-221
        • Santa Casa de Misericordia de Belo Horizonte
      • Belém, 브라질, 66.073-005
        • CTO Centro De Tratamento Oncologico LTDA
      • Curitiba, 브라질, 81520-060
        • Liga Paranaense de Combate ao Cancer
      • Jaú, 브라질, 17.210-080
        • Fundacao Doutor Amaral Carvalho
      • Porto Alegre, 브라질, 91350 200
        • Hospital Nossa Senhora da Conceicao S A
      • Salvador, 브라질, 40170 070
        • Nucleo de Oncologia da Bahia Oncoclinicas
      • Santa Cruz do Sul, 브라질, 96835-100
        • Hospital Ana Nery Santa Cruz do Sul
      • São Paulo, 브라질, 01509 900
        • Fundacao Antonio Prudente A C Camargo Cancer Center
      • São Paulo, 브라질, 01246 000
        • Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo
      • Taubaté, 브라질, 12030-200
        • Servicos de Tratamento ao Cancer de Taubate LTDA - Instituto do Cancer Brasil Unidade Taubate
      • Vitória, 브라질, 29043-260
        • Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia
      • A Coruña, 스페인, 15006
        • Hosp Univ A Coruna
      • Alicante, 스페인, 03010
        • Hosp. Gral. Univ. de Alicante
      • Barcelona, 스페인, 08028
        • Hosp. Univ. Quiron Dexeus
      • Barcelona, 스페인, 08035
        • Hosp Univ Vall D Hebron
      • Jaén, 스페인, 23007
        • Hosp. Univ. de Jaen
      • Lugo, 스페인, 27003
        • Hosp. Univ. Lucus Augusti
      • Madrid, 스페인, 28007
        • Hosp. Gral. Univ. Gregorio Maranon
      • Málaga, 스페인, 29010
        • Hosp Regional Univ de Malaga
      • Seville, 스페인, 41014
        • Hosp. Ntra. Sra. de Valme
      • Buenos Aires, 아르헨티나, C1199
        • Hospital Italiano de Buenos Aires
      • CABA, 아르헨티나, C1122
        • IADT Instituto Argentino de Diagnostico y Tratamiento
      • Capital Federal, 아르헨티나, C1017
        • Centro Medico Austral
      • La Plata, 아르헨티나, B1900AXI
        • Hospital Italiano de La Plata
      • Mar del Plata, 아르헨티나, B7602
        • Hospital Privado de la Comunidad
      • Changzhou, 중국, 213004
        • Changzhou No 2 Peoples Hospital
      • Chengdoucun, 중국, 610041
        • West China Hospital
      • Chengdu, 중국, 610041
        • Sichuan Cancer Hospital
      • Guangzhou, 중국, 510080
        • The First Affiliated Hospital Sun Yat sen University
      • Hangzhou, 중국, 310003
        • The First Affiliated Hospital Zhejiang University School of Medicine
      • Harbin, 중국, 150040
        • Harbin medical university cancer hospital
      • Huizhou, 중국, 516001
        • Huizhou Municipal Central Hospital
      • Nanjing, 중국, 210000
        • Zhongda Hospital Southeast University
      • Shanghai, 중국, 200032
        • Fudan University Shanghai Cancer Center
      • Xi'an, 중국, 710061
        • The First Affiliated Hospital of Xian Jiaotong University
      • Zhengzhou, 중국, 450008
        • Henan Cancer Hospital
      • Adana, 터키 (Türkiye), 1060
        • Adana City Hospital
      • Ankara, 터키 (Türkiye), 06560
        • Gazi University Hospital
      • Ankara, 터키 (Türkiye), 06010
        • Gulhane Training and Research Hospital
      • Ankara, 터키 (Türkiye), 6800
        • Ankara Bilkent City Hospital
      • Istanbul, 터키 (Türkiye), 34147
        • Bakirkoy Training and Research Hospital
      • Istanbul, 터키 (Türkiye), 34295
        • I A U VM Medical Park Florya Hastanesi
      • Izmir, 터키 (Türkiye), 35100
        • Ege University Medical Faculty
      • Samsun, 터키 (Türkiye), 55420
        • Ondokuz Mayis University
      • Marseille, 프랑스, 13915
        • Hopital Nord
      • Nice, 프랑스, 06001
        • Hopital PASTEUR
      • Paris, 프랑스, 75005
        • Institut Curie

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Have histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC); Is treatment naive and not amenable to curative therapy including surgical resection or (chemo) radiation. Adjuvant or neoadjuvant therapy for Stage I, Stage II or Stage IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease
  • Have a tumor that harbors an epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution, as detected by an Food and Drug Administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA)-certified laboratory (sites in the United States) or an accredited local laboratory (sites outside of the United States) in accordance with site standard-of-care
  • A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants with a history of symptomatic brain metastases must have had all lesions treated as clinically indicated (that is, no current indication for further definitive local therapy). Any definitive local therapy to brain metastases must have been completed at least 14 days prior to randomization, and the participant can be receiving no greater than 10 milligram (mg) prednisone or equivalent daily for the treatment of intracranial disease
  • Can have prior or concurrent second malignancy (other than the disease under study) which natural history or treatment is unlikely to interfere with any study endpoints, safety, or the efficacy of the study treatment(s). For the amivantamab SC expansion cohorts: Due to the increased risk of skin cancer with ruxolitinib, participants with any prior or concurrent skin malignancies will be excluded
  • Sub-study: Participants must have new-onset or persistent (defined as non-responsive to standard of care [SoC]) Grade >=2 specific DAEIs of the scalp, face, or body, as defined by NCI-CTCAE Grading v5.0 for DAEIs (excluding paronychia)

Exclusion Criteria:

  • History of uncontrolled illness, including but not limited to uncontrolled diabetes; ongoing or active infection (includes infection requiring treatment with antimicrobial therapy [participants will be required to complete antibiotics 1 week prior to starting background anticancer treatment] or diagnosed or suspected viral infection). For the amivantamab SC expansion cohorts, this includes active localized serious infections; active bleeding diathesis; impaired oxygenation requiring continuous oxygen supplementation; refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption of background anticancer treatment or doxycycline/minocycline; psychiatric illness, social situation, or any other circumstances that would limit compliance with study requirements; any ophthalmologic condition that is clinically unstable; pre-existing skin condition that would prevent adequate evaluations of dermatologic toxicity, as determined by the investigator
  • Medical history of interstitial lung disease (ILD), including drug-induced ILD or radiation pneumonitis
  • Known allergy, hypersensitivity, or intolerance to the excipients of amivantamab, lazertinib, or to tetracyclines, doxycycline, minocycline, timolol*, ruxolitinib*, zinc*, corticosteroids* or their excipients or to any component of the enhanced dermatologic management (*for the amivantamab SC expansion cohorts)
  • Participant has received any prior systemic treatment at any time for locally advanced stage III B/C or metastatic stage IV disease (adjuvant or neoadjuvant therapy for stage I, II or IIIA disease is allowed if last dose administered more than 12 months prior to the development of locally advanced or metastatic disease)
  • Participant has an active or past medical history of leptomeningeal disease
  • Sub-study: Participants who have received prior treatment for epidermal growth factor receptor (EGFR)-induced DAEIs with JAK inhibitors (for Cohort A) or calcineurin inhibitors (for Cohort B)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Arm A: Enhanced Dermatologic Management

Participants will receive enhanced dermatologic management to reduce toxicities in skin and nail with doxycycline tablet or minocycline capsule, clindamycin topical lotion, chlorhexidine topical solution, and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) with amivantamab intravenously (Dose 1 for body weight [BW] less than 80 kilograms [kg] and Dose 2 for BW greater than or equal to [>=] 80 kg as IV infusion [Arm A]) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1).

Amivantamab will be administered.

다른 이름들:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

다른 이름들:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

활성 비교기: Arm B: Standard-of-Care Dermatologic Management

Participants will receive standard care for dermatologic management according to local practice to reduce dermatologic toxicities in skin and nail during background anticancer treatment of advanced or metastatic EGFR-mutated NSCLC with amivantamab administered as IV infusion plus lazertinib, dose and dosing schedule as same as experimental arm.

Amivantamab will be administered.

다른 이름들:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

다른 이름들:
  • JNJ-73841937

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

실험적: Sub-study: Cohort A: Ruxolitinib

Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade greater than or equal to [>=] 2, as defined by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE] v5.0) will be enrolled and receive reactive treatment with ruxolitinib in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib.

Amivantamab will be administered.

다른 이름들:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

다른 이름들:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Ruxolitinib will be used to the affected skin area.

실험적: Sub-study: Cohort B: Tacrolimus

Participants enrolled in Arms A and B of the main study who experience new-onset or persistent specific DAEIs (Grade >= 2, as defined by NCI-CTCAE v5.0) will be enrolled and receive reactive treatment with tacrolimus in the sub-study. Participants in the sub-study will continue to receive amivantamab and lazertinib.

Amivantamab will be administered.

다른 이름들:
  • JNJ-61186372

Lazertinib tablet will be administered orally.

다른 이름들:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Clindamycin lotion will be used as topical application on the scalp.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Tacrolimus will be used as topical application to the affected skin area.

실험적: Amivantamab Subcutaneous (SC) Expansion Cohort: Standard Schedule

Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per standard schedule. If a participant develops a dermatologic adverse event of interest (DAEI) they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1.

Lazertinib tablet will be administered orally.

다른 이름들:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Chlorhexidine solution will be used as topical application on hands and feet.

Noncomedogenic skin moisturizer will be used as topical application.

Ruxolitinib will be used to the affected skin area.

Amivantamab will be administered as SC injection.

다른 이름들:
  • JNJ-61186372

Zinc gluconate tablet will be administered.

Propranolol tablet will be administered.

Timolol will be used to the affected skin area.

Clobetasol shampoo will be used on the scalp.

실험적: Amivantamab SC Expansion Cohort: Modified Schedule

Participants will receive modified enhanced dermatologic management with oral doxycycline or minocycline, zinc gluconate and noncomedogenic skin moisturizer during background anticancer treatment of advanced or metastatic EGFR mutated NSCLC with amivantamab SC and lazertinib as per modified schedule. If a participant develops a DAEI they will receive early intervention as follows: for facial (ruxolitinib), for scalp (oral propranolol and clobetasol), for paronychia (chlorhexidine in addition to timolol) until documented disease progression using Response Evaluation Criteria in Solid Tumors version 1.1.

Lazertinib tablet will be administered orally.

다른 이름들:
  • JNJ-73841937

Doxycycline tablet will be administered orally.

Minocycline capsule will be administered orally.

Amivantamab will be administered as SC injection.

다른 이름들:
  • JNJ-61186372

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Number of Participants With Grade Greater Than or Equal to (>=) 2 Dermatologic Adverse Events of Interest (DAEIs) Within 12 Weeks After Initiation of Anticancer Treatment
기간: Up to 12 weeks after initiation of anticancer treatment

Number of participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI-CTCAE) Version (v) 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 weeks after initiation of anticancer treatment

2차 결과 측정

결과 측정
측정값 설명
기간
Number of Participants With DAEIs by Severity Based on NCI-CTCAE v 5.0
기간: Up to 12 weeks after initiation of anticancer treatment

Number of participants with DAEIs by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 12 weeks after initiation of anticancer treatment
Number of Participants With Grade >=2 DAEIs Within 6 Months After Initiation of Anticancer Treatment Based on NCI-CTCAE v 5.0
기간: Up to 6 months after initiation of anticancer treatment

Number of participants with Grade >=2 DAEIs within 6 months after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported.

Up to 6 months after initiation of anticancer treatment
Number of Grade >= 2 DAEI Per Participants
기간: Up to 12 months

Number of grade >= 2 DAEI per participants will be reported.

Up to 12 months
Time to First Occurrence of Grade >=2 DAEI
기간: Up to 12 months

Time to first occurrence of Grade >=2 DAEI will be reported.

Up to 12 months
Time to Resolution of Grade >= 2 DAEI
기간: Up to 12 months

Time to resolution of Grade >= 2 DAEI will be reported.

Up to 12 months
Number of Participants With Paronychia by Severity Based on NCI-CTCAE v 5.0
기간: Up to 6 months after initiation of anticancer treatment

Number of participants with paronychia by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 6 months after initiation of anticancer treatment
Number of Participants With Scalp Rash by Severity Based on NCI-CTCAE v 5.0
기간: Up to 12 months after initiation of anticancer treatment

Number of participants with scalp rash by severity based on NCI-CTCAE v 5.0 will be reported.

Up to 12 months after initiation of anticancer treatment
Change From Baseline in Skindex Symptoms Domain Score up to 12 Months
기간: Baseline, up to Month 12

Change from baseline in skindex symptoms domain score up to 12 months will be reported. The score of quality of life will be assessed using the Skindex-16 questionnaire. Skindex-16 is used for participants to rate skin conditions.

Baseline, up to Month 12
Change From Baseline in Patient's Global Impression-Severity (PGI-S) Rash up to 12 Months
기간: Baseline, up to Month 12

Change from baseline in PGI-S rash up to 12 months will be reported. Participant quality of life will be evaluated using PGI-S Rash. PGI-S is a single-item questionnaire assessing participants disease severity on a 7-point response scale.

Baseline, up to Month 12
Change From Baseline in European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC-QLQ-C30) Score up to 12 Months
기간: Baseline, up to Month 12

Change from baseline in EORTC-QLQ-C30 score up to 12 months will be reported. EORTC-QLQ-C30 is a core 30-item questionnaire for evaluating the health-related quality of life (HRQoL) of participants participating in cancer clinical studies.

Baseline, up to Month 12
Change From Baseline in EuroQol 5 - Dimension (EQ-5D) Patient-reported Outcome (PRO) up to 12 Months (for Amivantamab Subcutaneous Expansion Cohort Only)
기간: Baseline, up to Month 12

The EQ-5D questionnaire is a brief, generic HRQOL assessment that can that can also be used to incorporate participant preferences into health economic evaluations. The EQ-5D questionnaire assesses HRQOL in terms of degree of limitation on 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) and as overall health using a visual analog scale with response options ranging from 0 (worst imaginable health) to 100 (best imaginable health). Lower scores indicate worsening. EQ-5D scores include EQ-5D valuation index score (a weighted scoring of the 5 dimension scores with a possible range from 0 to 1), EQ-5D visual analog scale (VAS) is a vertical VAS with scores ranging from 0 (worst imaginable health) to 100 (perfect health), and EQ5D descriptive system scores (five scores reflecting each of the 5 EQ-5D health dimensions ranging from 0 [no limitation] to 4 [incapacity]).

Baseline, up to Month 12
Percentage of Participants With Dose Reductions, Dose Interruptions, and Dose Discontinuations of Anticancer Treatment due to DAEIs
기간: Up to 12 months

Percentage of participants with dose reductions, dose interruptions, and dose discontinuations of anticancer treatment due to DAEIs will be reported.

Up to 12 months
Relative Dose Intensity (RDI) of Anticancer Treatment
기간: Up to 12 months

Relative dose intensity of anticancer treatment will be reported. The relative dose intensity is defined as the ratio of total actually received dose versus total prescribed dose.

Up to 12 months
Percentage of Participants With Venous Thromboembolism (VTE) Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0
기간: Up to 12 months

Percentage of participants with VTE AEs (pulmonary embolism and deep vein thrombosis) by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to 12 months
Percentage of Participants With Adverse Events (AEs) by Severity Based on NCI-CTCAE v 5.0
기간: Up to 12 months

Percentage of participants with AEs by severity based on NCI-CTCAE v 5.0 will be reported. An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention.

Up to 12 months
Progression Free Survival (PFS)
기간: Up to 12 months

PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or death due to any cause, whichever occurs first.

Up to 12 months
Overall Response Rate (ORR)
기간: Up to 12 months

ORR is defined as the percentage of participants who achieve a partial response (PR) or better response using RECIST v1.1 as assessed by the investigator.

Up to 12 months
Duration of Response (DoR)
기간: Up to 12 months

DOR will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the RECIST v1.1 response criteria.

Up to 12 months
Amivantamab SC Expansion Cohorts: Number of Participants With Grade >= 2 DAEIs Within 12 Weeks After Initiation of Anticancer Treatment
기간: Up to 12 weeks after initiation of anticancer treatment

Participants with Grade >= 2 DAEIs within 12 weeks after initiation of anticancer treatment based on NCI-CTCAE v 5.0 will be reported. DAEIs includes rash, dermatitis acneiform, pruritus, skin fissures, acne, folliculitis, erythema, eczema, rash maculo-papular, skin exfoliation, skin lesion, skin irritation, dermatitis, rash erythematous, rash macular, rash popular, rash pruritic, rash pustular, dermatitis contact, dermatitis exfoliative generalized, drug eruption, dyshidrotic eczema, eczema asteatotic and paronychia. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 weeks after initiation of anticancer treatment
Amivantamab SC Expansion Cohorts: Percentage of Participants With an Improvement in DAEI After Starting Early Intervention
기간: Up to 12 months

Percentage of participants showing an improvement in DAEI by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 months
Amivantamab SC Expansion Cohorts: Time to Improvement of DAEIs After Starting Early Intervention
기간: Up to 12 months

Time to improvement of DAEIs by a minimum of 1 NCI-CTCAE grade after starting early intervention will be reported. As per NCI-CTCAE v 5.0, severity scale ranges from Grade 1 (mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, and Grade 5= death related to adverse event.

Up to 12 months

기타 결과 측정

결과 측정
측정값 설명
기간
Percentage of Participants Achieving Best Response for the Dermatologic Adverse Event
기간: Up to 12 weeks

Participants achieving best response within 12 weeks of treatment defined as NCI-CTCAE level of the dermatologic adverse event improvement by at least 1 level will be reported.

Up to 12 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2024년 2월 16일

기본 완료 (추정된)

2027년 5월 31일

연구 완료 (추정된)

2030년 6월 30일

연구 등록 날짜

최초 제출

2023년 11월 2일

QC 기준을 충족하는 최초 제출

2023년 11월 2일

처음 게시됨 (실제)

2023년 11월 7일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 2일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다